Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 7, 2017 (10 years ago)

ATENOLOL Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Tablets/Capsules: Customer complaint that a bottle of atenolol 50 mg Tablets USP contained a paroxetine 20 mg tablet.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

ATENOLOL Tablets, USP, 50 mg, 30-count bottle, Rx only, Distributed by: The Kroger Co., 1014 Vine Street, Cincinnati, OH 45202; Manufactured for: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534; Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045; NDC 68645-493-54.

Affected NDC 68645-0493-54

Compare with the code on your package — it is the most precise check available.

Drug: Atenolol Category: Blood Pressure Medication

Recalling firm
Legacy Pharmaceutical Packaging LLC
NDC code
68645-493-54
Origin
MO, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0606-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Atenolol recalls

See all
Class I · High risk

Atenolol Tablets

Label Mix - up; a bottle labeled as Atenolol 25mg Tablets contained Clopidogrel 75mg Tablets

Terminated Labeling / mix-up Golden State Medical Supply Inc. NDC 60429-027-10 D-0019-2023
Class II · Moderate risk

ATENOLOL Tablets

Presence of Foreign Tablets/Capsules: Customer complaint that a bottle of atenolol 50 mg Tablets USP contained a paroxetine 20 mg tablet.

Terminated Particulate / foreign matter Zydus Pharmaceuticals USA Inc NDC 68382-023-01 D-0605-2017
Class II · Moderate risk

ZyGenerics ATENOLOL Tablets

Superpotent Drug: A complaint was reported by a pharmacist who stated several tablets were noticeably thicker in appearance.

Terminated Wrong potency / content Zydus Pharmaceuticals USA Inc NDC 68382-022-01 D-0007-2015
Class II · Moderate risk

ATENOLOL Tablet

Labeling:Label Mixup; ATENOLOL, Tablet, 12.5 mg (1/2 of 25 mg) may be potentially mislabeled as VITAMIN B COMPLEX WITH C/FOLIC ACID, Tablet, NDC 60258016001, Pedigree: AD73652_19, EXP: 5/30/2014; PIROXICAM, Capsule, 10 mg, NDC 00093075601, Pedigree: AD21836_1, EXP: 3/31/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-679-2014

Other recalls by Legacy Pharmaceutical Packaging LLC

All 2017 recalls
Class II · Moderate risk

Sertraline Tablets

CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.

Ongoing cGMP deviation Legacy Pharmaceutical Packaging LLC NDC 68645-523-54 D-0205-2024
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: Detection of trace amounts of N-Methylnitrosobutyric acid (NMBA) impurity found in the Active Pharmaceutical Ingredient (API)

Ongoing Nitrosamine impurity Legacy Pharmaceutical Packaging LLC NDC 68645-494-54 D-1263-2019
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected.

Terminated Nitrosamine impurity Legacy Pharmaceutical Packaging LLC NDC 68645-494-54 D-1075-2019